SCHEMBL25792289

SCHEMBL25792289

COc1ncnc(C2CC2)c1-c1cc2n(n1)CCC(C)N2C(=O)OC(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.35
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 2/20 0.35
TSHR P16473 2/20 0.35
KMT2A Q03164 2/20 0.35
HSD17B10 Q99714 2/20 0.35
HTT P42858 2/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
GRM5 P41594 1/20 0.35
PIK3CD O00329 6/20 0.34
PIK3CA P42336 2/20 0.33
PIK3CB P42338 2/20 0.33
PIK3CG P48736 2/20 0.33
USP1 O94782 4/20 0.33
USP2 O75604 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30320412 0.84 GPR119 (0.36) HPGDKDM4EALDH1A1MEN1TSHR
SCHEMBL25247862 0.84 GPR119 (0.36) HPGDKDM4EALDH1A1MEN1TSHR
SCHEMBL25792290 0.72 GRM5 (0.42) KDM4EGRM5MAPTGPR119
SCHEMBL25792288 0.70 USP1 (0.34) USP1RORCWDR48
SCHEMBL31346312 0.69 JAK2 (0.39) ALDH1A1HTTPIK3CDPIK3CAPIK3CB
SCHEMBL25792734 0.68 RORC (0.33) USP1RORCWDR48
SCHEMBL30320366 0.68 CYP1A2 (0.38) USP1RORCWDR48
SCHEMBL25292824 0.68 CYP1A2 (0.38) USP1RORCWDR48
SCHEMBL25202089 0.67 PIK3CD (0.39) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL30443199 0.67 PIK3CD (0.39) PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219965-A1 NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS USP1, USP8, USP7 HPGD 3731/4885KDM4E 679/4885ALDH1A1 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.